Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


Prospective, double-blind, randomised study of the efficacy of ketamine for oropharyngeal mucositis pain


To see complete record on anzctr.org.au, please visit this link

Id: ACTRN12619000108112p

Organisation Name: Monash Health

Overal Status: Not yet recruiting

Start Date: 11/02/2019

Brief Summary: This study looks at the effectiveness of a new treatment for cancer therapy-related oropharyngeal mucositis (throat or mouth ulceration) pain.
Who is it for?
You may be eligible for this study if you are aged 18 or over and have cancer treatment-related oropharyngeal mucositis (throat or mouth ulceration) pain.

Study details
This is a randomised controlled research project, meaning that patients will be assigned by chance to either the experimental arm to receive midazolam and ketamine, or to the control arm to receive midazolam alone. This is also a blinded study, meaning that study doctors and patients will not know which group a patient has been assigned to until the end of the study. Participants in both groups will receive medication through a needle in the arm for up to 5 days. All participants will provide blood samples and answer questionnaires.

It is hoped this research will demonstrate ketamine is an effective drug in treating mucositis pain, and this treatment may then be offered to all suitable patients who are also experiencing mucositis pain.

Countries:
  • Australia


Total execution time in seconds: 0.085386991500854